Amanta Healthcare IPO Opens Next Week – Key Details To Know Before You Subscribe

Pharmaceutical company Amanta Healthcare is set to open its Rs 126-crore initial public offering (IPO) for subscription next week. The issue will consist solely of a fresh issue of 10 million shares of face vlaue Rs 10 each. Beeline Capital Advisors Pvt. Ltd. is acting as the book-running lead manager, while MUFG Intime India Pvt. Ltd. will serve as the registrar to the issue. 

According to the red herring prospectus (RHP), 50 per cent of the net issue is reserved for qualified institutional buyers (QIBs), 35 per cent will be made available to retail investors, and 15 per cent has been earmarked for non-institutional investors (NIIs), including high-net-worth individuals.

Amanta Healthcare IPO Key Details

Subscription Window: Monday, September 1 to Wednesday, September 3

Allotment Date: Thursday, September 4

Refund Initiation: Monday, September 8

Share Credit Date: Monday, September 8

Listing Date: Tuesday, September 9

Listing At: NSE, BSE

Price Band: Rs 120 to Rs 126

Lot Size: 119 shares

Minimum Investment (Retail): Rs 14,994

Amanta Healthcare IPO GMP, Estimated Listing Price

The Amanta Healthcare IPO is commanding a grey market premium (GMP) of Rs 22 per share, according to websites that track GMP of upcoming IPOs.

At the upper price band of Rs 126, the estimated listing price comes at Rs 148 per share, a premium of 17.46 per cent.

Amanta Healthcare IPO Objectives

Amanta Healthcare plans to utilise the net proceeds from its Rs 126-crore IPO primarily for expansion at its Hariyala facility in Kheda, Gujarat. The company will allocate about Rs 70 crore for setting up a new manufacturing line of SteriPort and Rs 30.13 crore for a new SVP line. The remaining funds will be used for general corporate purposes.

Amanta Healthcare Financial Performance

P&L Statement:

Amanta Healthcare reported revenue of Rs 276.09 crore in FY25, as against Rs 281.60 crore in FY24 and Rs 262.69 crore in FY23.

The company's earnings before interest, tax, depreciation and amortisation (Ebitda) came in at Rs 61.05 crore in FY25, as against Rs 58.75 crore in FY24 and Rs 56.30 crore in FY23.

Profit after tax (PAT) stood at Rs 10.50 crore in FY25, as against Rs 3.63 crore in FY24 and a loss of Rs 2.11 crore in FY23.

Its earnings per share (EPS) at the end of FY25 stood at 3.71, as against Rs 1.35 in FY24 and a negative 0.79 in FY23.

Cash Flow Statement:

Net cash flow from operating activities was Rs 46.62 crore in FY25, as against Rs 58.07 crore in FY24 and Rs 42.58 crore in FY23.

Net cash used in investing activities in FY25 stood at Rs 24.47 crore, Rs 10.32 crore in FY24 and Rs 6.53 crore in FY23.

Net cash used in financing activities for FY25 stood at Rs 23.46 crore, for FY24 it was Rs 46.32 crore, and for FY23 it was Rs 42.32 crore.

Assets & Liabilities:

The company reported assets worth Rs 381.76 crore in FY25, as against Rs 352.12 crore in FY24 and Rs 374.06 crore in FY23.

Total equity and liabilities of the company by the end of FY25 was Rs 381.75 crore, for FY24 it was Rs 352.12 crore, and for FY23 it was Rs 374.06 crore.

As of March 31, 2025, the company had a reserve of Rs 67.55 crore.

About Amanta Healthcare

Amanta Healthcare is a pharmaceutical company engaged in the development, manufacturing and marketing of a diverse range of sterile liquid products. According to its RHP, the company’s portfolio includes parenteral products packed in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company manufactures both large volume parenterals (LVPs) and small volume parenterals (SVPs) across six therapeutic segments.

The company markets its products through three strategic business units: (a) national sales, (b) international sales, and (c) product partnering with various Indian and foreign pharmaceutical companies.

Amanta Healthcare has a diverse generics portfolio of over 45 products, marketed under its own brands in India through a network of more than 320 distributors and stockists. It also exports to several international markets, including Africa, Latin America and the UK. In fiscal 2025, the company exported its branded products to 21 countries.